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Introduction: Type I interferons (IFNs) are implicated in the pathogenesis of systemic sclerosis (SSc). MEDI-546 is an
investigational human monoclonal antibody directed against the type I IFN receptor. This Phase 1 study evaluated
the safety/tolerability, pharmacokinetics (PK), immunogenicity, and pharmacodynamics (PD) of single and multiple
intravenous doses of MEDI-546 in adults with SSc.
Methods: Subjects (≥18 years) with SSc were enrolled in an open-label, dose-escalation study to receive single
(0.1, 0.3, 1.0, 3.0, 10.0, or 20.0 mg/kg), or 4 weekly intravenous doses (0.3, 1.0, or 5.0 mg/kg/week) of MEDI-546.
Subjects were followed for 12 weeks. Safety assessments included adverse events (AEs), laboratory results, and viral
monitoring. Blood samples were collected from all subjects for determination of PK, presence of anti-drug
antibodies (ADAs), and expression of type I IFN-inducible genes.
Results: Of 34 subjects (mean age 47.4 years), 32 completed treatment and 33 completed the study. Overall, 148
treatment-emergent AEs (TEAEs) were reported (68.9% mild, 27.7% moderate). TEAEs included one grade 1 infusion
reaction (5.0 mg/kg/week multiple dose). Of 4 treatment-emergent serious AEs (skin ulcer, osteomyelitis, vertigo,
and chronic myelogenous leukemia (CML)), only CML (1.0 mg/kg/week multiple dose) was considered possibly
treatment-related. MEDI-546 exhibited non-linear PK at lower doses. ADAs were detected in 5 subjects; no apparent
impact on PK was observed. Peak inhibition of the type I IFN signature in whole blood was achieved within 1 day
and in skin after 7 days.
Conclusion: The safety/tolerability, PK, and PD profiles observed in this study support further clinical development
of MEDI-546.
Trial Registration: ClinicalTrials.gov NCT00930683Introduction
Systemic sclerosis (SSc) is an autoimmune multisystem
disease of unknown etiology, characterized by structural
abnormalities in small blood vessels and excessive depo-
sition of extracellular matrix components [1,2]. Patients
with diffuse SSc have a greater likelihood of organ dam-
age, reduced quality of life, and long-term morbidity* Correspondence: Avram.Goldberg@nyumc.org
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reproduction in any medium, provided the orand mortality, leading to a high economic and patient
burden [3,4].
Current therapies for SSc are generally aimed at control-
ling symptoms, and do not address the underlying causes
of the disease [5]. A recent report from the German
Network for Systemic Scleroderma showed that 41% of
patients with SSc were treated with corticosteroids and
36% received immunosuppressive agents, despite a lack of
robust evidence demonstrating the efficacy of these treat-
ments [6]. High-dose corticosteroid therapy (≥15 mg/day)
has been associated with the development of renal crisis, aral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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immunosuppressive therapy has demonstrated some effi-
cacy in clinical studies, it does not appear to provide bene-
fits during later phases of SSc, and long-term usage is
limited by its potential toxicity [5]. Currently, there are
no effective disease-modifying treatments available for
patients with SSc [8]. Considering the high mortality of
SSc, there is a significant unmet need for novel therapies
that clearly control or alter the aberrant fibrotic pathways
of the disease, with acceptable toxicities [9].
An increasing body of evidence suggests that type I
interferons (IFNs), may play a role in SSc pathogenesis
[10]. In some studies, elevated levels of type I IFNs have
been observed in the blood of patients with SSc [11,12].
In addition, increased expression of type I IFN-induced
genes and proteins has been observed in the blood and
skin of patients with SSc [13-17]. Furthermore, IFN
therapy has been implicated in the development or
exacerbation of SSc or sclerodermatous-like disease
[18,19]. These studies indicate that the type I IFN path-
way is activated in patients with SSc and that these pa-
tients may benefit from anti-IFN therapy.
All type I IFNs bind to the same heterodimeric type I
IFNα receptor (IFNAR), comprising subunits IFNAR1 and
IFNAR2 [20,21]. MEDI-546 is an investigational human
immunoglobulin G1 kappa monoclonal antibody directed
against IFNAR1. By blocking type I IFN-mediated sig-
naling, MEDI-546 suppresses the receptor-mediated bio-
logical activity of all type I IFNs (unpublished results).
In this study, the safety profile (primary objective)
and pharmacokinetics (PK), immunogenicity, and pharma-




This was a Phase 1, multicenter, open-label, dose-escal-
ation study of single and multiple IV doses of MEDI-546
in adult subjects with SSc. The study is registered on
ClinicalTrials.gov (Study MI-CP180; NCT00930683). The
study protocol, protocol amendments, and subject in-
formed consent documents were approved by Institutional
Review Boards (IRBs). A list of the IRBs is provided below.
Written informed consent was obtained from all subjects
before study entry or any study-specific activities were car-
ried out. An electronic data capture system was utilized
for this study.
The primary objective was to evaluate the safety and
tolerability of single and multiple IV escalating doses of
MEDI-546. Secondary objectives of the study were to assess
the PK, immunogenicity potential, and PD of MEDI-546.
Following a 28-day screening period, eligible subjects
were randomized into 9 groups: 6 groups received 1 of 6
single MEDI-546 doses (0.1, 0.3, 1.0, 3.0, 10.0, or
20.0 mg/kg) sequentially, and 3 groups received 1 of 3
multiple MEDI-546 doses (0.3, 1.0, or 5.0 mg/kg/week, 4
doses in total) (Figure 1). The single doses were started
at 0.1 mg/kg. The single doses were escalated sequen-
tially. For single-dose groups ≤10.0 mg/kg, dose esca-
lation decisions were made based on the review of safety
data up to day 7 in the preceding lower dose group. The
20.0 mg/kg single-dose group and all multiple-dose
groups were enrolled simultaneously, after the cumulative
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MEDI-546 was administered as IV infusion over ≥60 mi-
nutes. Administration occurred on day 0 for single-dose
groups, with follow-up until day 84, and on days 0, 7, 14,
and 21 for multiple-dose groups, with follow-up until day
105. Evaluations were scheduled on study days 0, 1, 7, 14,
21, 28, 56, and 84 for single-dose groups and, additionally,
on days 22 and 105 for multiple-dose groups.
Subjects
Adults aged ≥18 years who met the American College of
Rheumatology preliminary criteria for SSc [22] were en-
rolled in the study. All study participants were required to
have at least moderate skin thickening (≥2 by modified
Rodnan Skin Score [mRSS]) in an area suitable for repeat
biopsy. Stable concomitant medication to treat SSc or
other medical conditions was allowed, unless the treat-
ment met the following exclusion criteria. Subjects were
excluded if they had received any of the following medica-
tions within 28 days before study day 0: cyclophospha-
mide, systemic cyclosporine, or thalidomide. Subjects
were excluded if they had received fluctuating doses or in
excess of permitted doses of antimalarials (hydroxychlor-
quine >600 mg/day), mycophenolate mofetil (>3 g/day),
methotrexate (>25 mg/week), leflunomide (>20 mg/day
within 6 months of study entry), or azathioprine (>3 mg/
kg/week); any antiviral treatment; or an investigational
treatment within 28 days of study day 0. Also excluded
were subjects who had received prednisone (>20 mg/day
or fluctuating doses) or nonsteroidal anti-inflammatory
drugs (fluctuating doses) within 14 days of study day 0.
Other exclusions included history of primary immuno-
deficiency, severe viral infection, herpes zoster infection,
cancer, and alcohol or drug abuse.
Safety and tolerability
Adverse events (AEs) and serious AEs (SAEs) were moni-
tored at screening and at each scheduled evaluation visit.
AEs and SAEs were graded on a scale of 1–5 using the
National Cancer Institute Common Terminology Criteria
for Adverse Events, version 4.03 [23] and by relationship
to study drug. Grade refers to the severity of the AE: grade
1: mild AE; grade 2: moderate AE; grade 3: severe AE;
grade 4: life-threatening or disabling AE; grade 5: death
related to AE.
Hematology, serum chemistry, and urinalysis were as-
sessed at screening and at each scheduled evaluation visit,
except for study days 1 and 22 (multiple doses only). Viral
monitoring was performed on days 0 (before dosing), 28,
56, 84, and 105. Surveillance was performed for cyto-
megalovirus (CMV), Epstein-Barr virus (EBV), herpes
simplex virus (HSV-1 and HSV-2), and human papilloma
virus (HPV). Oropharyngeal and vaginal swabs were cul-
tured for HSV-1 and HSV-2, vaginal swabs were tested forHPV, and blood samples were tested for CMV and EBV.
HPV DNA testing was performed using the Hybrid Cap-
ture 2 High-Risk assay (HC2), with a sensitivity and spe-
cificity range of 81–93% and 80–94%, respectively [24].
CMV, EBV and HSV testing were performed at ACM
Global Central Laboratory (Rochester, NY, USA). CMV
and EBV were detected using quantitative real-time poly-
merase chain reaction assays. HSV was identified by its
characteristic cytopathic effect; virus typing was accom-
plished using fluorescent antibodies against HSV-1 and
HSV-2.
Pharmacokinetics
Blood samples for PK assessments were collected at
each scheduled evaluation visit. Serum concentrations of
MEDI-546 were measured using a validated electro-
chemiluminescent (ECL) assay. In this assay, biotinylated
IFNAR1 and a sulfo-TAG labeled monoclonal antibody
specific for MEDI-546 were utilized as the capturing and
detecting reagents, respectively. The quantitation range
of the assay was 20–1280 ng/mL, for 1:10 diluted human
serum.
Immunogenicity
Blood samples for anti-drug antibody (ADA) assess-
ments were taken on days 0 (pre-dose), 28, 56, 84, and
105. The presence of ADAs in human serum samples
was determined using an ECL, solution-phase, bridging
immunoassay. Positive titers, expressed as reciprocal
dilutions, were defined as 1:30 or higher.
Auto-antibody levels, including antinuclear antibody
and anti-topoisomerase I (anti-SCL-70), were measured
on day 0, as part of the baseline SSc evaluation.
Pharmacodynamics
Five type I IFN-inducible genes (RSAD2, IFI44, IFI44L,
IFI27, IFI6) were selected as pharmacodynamics markers
for MEDI-546 based on their prevalence and magnitude
of overexpression in patients with SSc as compared with
healthy controls [25,26]. Total RNA was extracted from
blood and skin biopsies using the PAXgene Blood RNA kit
and the Qiagen RNeasy Fibrous Tissue Mini kit (Hilden,
Germany), respectively. RNA purity and concentration
were determined spectrophotometrically (260/280 > 1.9).
RNA quality was assessed on an Agilent 2100 Bioanalyzer
using the RNA 6000 Nano LabChip® (Santa Clara, CA,
USA).
The expression level of the 5-gene marker in whole
blood and skin was measured using Affymetrix Human
Genome U133 Plus arrays (Santa Clara, CA, USA) [25].
Blood samples were procured at each evaluation visit,
except for days 21 and 22, and skin biopsies were collected
on days 0, 7 (single doses only), and 28 (multiple doses
only). Transcript profiling was conducted according to
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positive gene signatures as >2.9 for skin and >1.8 for blood
and the details of score generation are included in the
Wang publication [26].
Statistical methods
No formal sample size calculation was performed, as the
primary endpoint was safety and tolerability. A sample
size of 33 subjects was planned, with 53 being the maxi-
mum number of subjects allowed in the study. The safety
population, comprising all subjects who received MEDI-
546, was used for safety and tolerability evaluations and
for measurements of PD; the evaluable population for PK
included all subjects in the safety population with ≥1 valid
MEDI-546 serum concentration assessment; the evaluable
population for immunogenicity included all subjects in
the safety population with ≥1 valid immunogenicity test
result post dose.
No formal statistical hypothesis testing was planned for
the primary endpoint. Noncompartmental PK data ana-
lysis was performed using WinNonlin Professional version
5.2 (Pharsight Corp, St Louis, MO, USA). The maximum
serum concentration (Cmax), area under the serum
concentration-time curve from 0 to infinity (AUCinf; single
doses only), AUC from time 0 to 7 days post dose admini-
stration (AUC0–7; multiple doses only), serum elimination
half-life (t1/2), and systemic clearance (CL) were calculated
and reported. Incidences of positive ADA were summa-
rized for each dose group and all groups combined.
Type I IFN gene signature scores were calculated as
median-fold change in the expression of 5 IFN-inducible
genes in SSc subjects, with respect to a pooled panel of
healthy volunteers. Positive gene signature scores were
defined as >2.9 in whole blood and >1.8 in skin, using
blood and skin specimens from 54 and 30 healthy volun-
teers, respectively (data on file). Subjects were divided
into signature positive and signature negative groups
based on type I IFN signature scores at baseline.
Results
Baseline characteristics
The study started on 19 August 2009 and was completed
on 14 July 2011. Thirty-four subjects from 7 US sites were
enrolled, of which 33 subjects completed the study, with 1
subject in the 5.0 mg/kg/week multiple-dose group dis-
continuing from the study for other reasons. Most sub-
jects were female (79.4%), white (73.5%), and had diffuse
cutaneous SSc (94.1%) and Raynaud’s phenomenon
(97.1%). Mean mRSS was 23.3. Overall, 22 subjects
(64.7%) had positive type I IFN gene signature in whole
blood, 15 (44.1%) in skin, and 7 (20.6%) had a history of
viral reactivation. Positive antinuclear antibodies and anti-
SCL-70 antibodies were found in 24 (70.6%) and 11 (32.4%)
subjects, respectively. The most common medications usedat baseline were corticosteroids ≤10 mg/day (n = 12; 35.3%)
and methotrexate (n = 11; 32.4%) for >6 months. Baseline
demographic and disease characteristics by MEDI-546
dose group are summarized in Table 1.
All 34 subjects were included in the safety population
and the evaluable population for PK. The population for
ADA comprised 32 subjects; 2 subjects in the 5.0 mg/kg/
week multiple-dose group were excluded for disconti-
nuing treatment.
Safety and tolerability assessments
In total, 148 treatment-emergent AEs (TEAEs) were re-
ported during the study, with all 34 subjects repor-
ting ≥1 TEAE. The most frequently reported TEAEs
(incidence >10% of total population) were upper res-
piratory tract infection (n = 10; 29.4%), headache (n = 7;
20.6%), diarrhea (n = 6; 17.6%), nausea (n = 6; 17.6%), arth-
ralgia (n = 4; 11.8%), fatigue (n = 4; 11.8%), and pruritus
(n = 4; 11.8%) (Table 2). Most TEAEs were grade 1
(68.9%) or grade 2 (27.7%) in intensity. Two grade 3
TEAEs were reported in the 3.0 mg/kg single-dose group
(osteomyelitis and skin ulcer) and 3 in the 5.0 mg/kg/week
multiple-dose group (vertigo, musculoskeletal chest pain,
and musculoskeletal pain), and were considered unrelated
to treatment. No relationship was apparent between
MEDI-546 dose and nature, frequency, or severity of
TEAEs reported.
Three subjects (8.8%) reported 4 treatment-emergent
SAEs (TESAEs): 1 subject in the 3.0 mg/kg single-dose
group (osteomyelitis and skin ulcer), 1 subject in the
5.0 mg/kg/week multiple-dose group (vertigo), and 1 sub-
ject in the 1.0 mg/kg/week multiple-dose group (chronic
myelogenous leukemia [CML]). Of these, only CML, with
onset 10 months after study completion, was considered
possibly related to treatment. Two subjects in the 5.0 mg/
kg/week multiple-dose group discontinued treatment: 1
treatment discontinuation was due to TEAEs of head
injury and vertigo, and the other due to a non-TESAE of
normochromic normocytic anemia, with onset prior to
administration of the first MEDI-546 dose. Both events
were considered unrelated to treatment. There were no
deaths in this study.
Six subjects had abnormal laboratory results, with 3
abnormalities reported as TEAEs (Table 2). Of the 6
subjects, 4 also had abnormal values at baseline and 4
had a history of similar findings. Most events were tran-
sient and resolved by the following evaluation visit. One
laboratory abnormality of low red blood cell count, re-
ported as a grade 1 TEAE of anemia, was considered
possibly related to treatment.
Infections occurred in 14 subjects (41.2%). All infections
were grade 1 or 2 in severity, except for 1 grade 3 osteo-
myelitis in the 3.0 mg/kg single-dose group that lasted
8 days and was considered remotely related to treatment.





















(n = 1) (n = 4) (n = 4) (n = 4) (n = 4) (n = 4) (n = 4) (n = 4) (n = 5) (N = 34)
Age, mean (SD), years 41.0 (NA) 58.3 (10.0) 45.0 (7.1) 33.0 (10.4) 48.0 (12.5) 45.5 (9.5) 42.5 (11.4) 49.3 (9.5) 57.2 (12.3) 47.4 (12.0)
Female, n (%) 1 (100.0) 3 (75.0) 4 (100.0) 3 (75.0) 4 (100.0) 3 (75.0) 2 (50.0) 3 (75.0) 4 (80.0) 27 (79.4)
White, n (%) 1 (100.0) 3 (75.0) 2 (50.0) 2 (50.0) 2 (50.0) 3 (75.0) 4 (100.0) 4 (100.0) 4 (80.0) 25 (73.5)
Weight, mean (SD), kg 63.5 (NA) 57.7 (5.4) 71.7 (26.8) 72.8 (30.1) 73.4 (28.2) 68.7 (13.6) 87.8 (11.6) 75.9 (33.7) 72.2 (21.8) 72.3 (21.8)
Diffuse cutaneous systemic SSc, n (%) 1 (100.0) 4 (100.0) 4 (100.0) 4 (100.0) 4 (100.0) 4 (100.0) 3 (75.0) 4 (100.0) 4 (80.0) 32 (94.1)
Raynaud’s, n (%) 1 (100.0) 4 (100.0) 4 (100.0) 4 (100.0) 4 (100.0) 4 (100.0) 3 (75.0) 4 (100.0) 5 (100.0) 33 (97.1)
mRSS, mean (SD) 16.0 (NA) 24.5 (6.6) 23.0 (11.0) 21.0 (2.4) 22.0 (10.4) 31.8 (12.2) 17.5 (5.1) 24.5 (10.1) 23.8 (7.9) 23.3 (8.6)
Positive type I IFN gene signaturea
Whole blood, n (%) 0 (0.0) 4 (100.0) 2 (50.0) 3 (75.0) 3 (75.0) 3 (75.0) 1 (25.0) 3 (75.0) 3 (60.0) 22 (64.7)
Skin, n (%) 0 (0.0) 2 (50.0) 3 (75.0) 1 (25.0) 4 (100.0) 1 (25.0) 0 (0.0) 3 (75.0) 1 (20.0) 15 (44.1)
History of viral reactivation, n (%) 0 (0.0) 1 (25.0) 0 (0.0) 0 (0.0) 0 (0.0) 2 (50.0) 1 (25.0) 2 (50.0) 1 (20.0) 7 (20.6)
Positive antinuclear antibody, n (%) 1 (100.0) 2 (50.0) 4 (100.0) 4 (100.0) 3 (75.0) 2 (50.0) 3 (75.0) 3 (75.0) 2 (40.0) 24 (70.6)
Positive anti-SCL-70 antibody, n (%) 1 (100.0) 2 (50.0) 0 (0.0) 3 (75.0) 1 (25.0) 1 (25.0) 2 (50.0) 0 (0.0) 1 (20.0) 11 (32.4)
Corticosteroids ≤10 mg/day
for <6 months, n (%) 0 (0.0) 1 (25.0) 2 (50.0) 0 (0.0) 1 (25.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 4 (11.8)
for >6 months, n (%) 0 (0.0) 0 (0.0) 2 (50.0) 3 (75.0) 1 (25.0) 3 (75.0) 0 (0.0) 1 (25.0) 2 (40.0) 12 (35.3)
Corticosteroids >10 and ≤20 mg/day
for <6 months, n (%) 0 (0.0) 1 (25.0) 1 (25.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 2 (5.9)
for >6 months, n (%) 0 (0.0) 1 (25.0) 0 (0.0) 2 (50.0) 2 (50.0) 1 (25.0) 0 (0.0) 0 (0.0) 0 (0.0) 6 (17.6)
Antimalarials for >6 months, n (%) 0 (0.0) 0 (0.0) 0 (0.0) 1 (25.0) 1 (25.0) 2 (50.0) 0 (0.0) 1 (25.0) 0 (0.0) 5 (14.7)
Methotrexate
for <6 months, n (%) 0 (0.0) 0 (0.0) 1 (25.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (25.0) 0 (0.0) 0 (0.0) 2 (5.9)
for >6 months, n (%) 0 (0.0) 1 (25.0) 1 (25.0) 3 (75.0) 2 (50.0) 2 (50.0) 0 (0.0) 1 (25.0) 1 (20.0) 11 (32.4)
aPositive type I IFN gene signature was defined as a baseline (day 0 pre-dose) fold change value >2.9 in whole blood and >1.8 in skin.





































(n = 1) (n = 4) (n = 4) (n = 4) (n = 4) (n = 4) (n = 4) (n = 4) (n = 5) (N = 34)
TEAEs
Total number of TEAEs 1 10 15 15 18 11 20 20 38 148
Total subjects reporting ≥1 TEAEs, n (%) 1 (100.0) 4 (100.0) 4 (100.0) 4 (100.0) 4 (100.0) 4 (100.0) 4 (100.0) 4 (100.0) 5 (100.0) 34 (100.0)
Upper respiratory tract infection, n (%)a 0 (0.0) 2 (50.0) 1 (25.0) 2 (50.0) 0 (0.0) 2 (50.0) 0 (0.0) 3 (75.0) 0 (0.0) 10 (29.4)
Headache, n (%)a 0 (0.0) 1 (25.0) 0 (0.0) 0 (0.0) 2 (50.0) 1 (25.0) 2 (50.0) 1 (25.0) 0 (0.0) 7 (20.6)
Diarrhea, n (%)a 0 (0.0) 0 (0.0) 3 (75.0) 0 (0.0) 0 (0.0) 1 (25.0) 0 (0.0) 1 (25.0) 1 (20.0) 6 (17.6)
Nausea, n (%)a 0 (0.0) 0 (0.0) 0 (0.0) 1 (25.0) 2 (50.0) 1 (25.0) 0 (0.0) 1 (25.0) 1 (20.0) 6 (17.6)
Arthralgia, n (%)a 0 (0.0) 0 (0.0) 1 (25.0) 0 (0.0) 1 (25.0) 0 (0.0) 1 (25.0) 1 (25.0) 0 (0.0) 4 (11.8)
Fatigue, n (%)a 0 (0.0) 0 (0.0) 1 (25.0) 0 (0.0) 1 (25.0) 0 (0.0) 1 (25.0) 1 (25.0) 0 (0.0) 4 (11.8)
Pruritus, n (%)a 0 (0.0) 0 (0.0) 1 (25.0) 0 (0.0) 1 (25.0) 0 (0.0) 0 (0.0) 1 (25.0) 1 (20.0) 4 (11.8)
Dizziness, n (%)a 0 (0.0) 0 (0.0) 1 (25.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 2 (40.0) 3 ( 8.8)
Musculoskeletal chest pain, n (%)a 0 (0.0) 0 (0.0) 1 (25.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 2 (40.0) 3 ( 8.8)
Urticaria, n (%)a 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (25.0) 0 (0.0) 2 (40.0) 3 ( 8.8)
Constipation, n (%)a 0 (0.0) 2 (50.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 2 (5.9)
Depression, n (%)a 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 2 (40.0) 2 (5.9)
Laboratory abnormalities
Anemiab,c, n (%) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (20.0) 1 (2.9)
Decreased hemoglobind, n (%) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (20.0) 1 (2.9)
Decreased absolute lymphocyte countd, n (%) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (20.0) 1 (2.9)
Elevated aspartate aminotransferase valuee, n (%) 0 (0.0) 1 (25.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (2.9)
Hyperglycemiab, n (%) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (25.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (2.9)
Hematuriab, n (%) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (25.0) 0 (0.0) 0 (0.0) 1 (2.9)
aPreferred term according to the Medical Dictionary for Regulatory Activities version 14.0.
bLaboratory abnormality reported as a TEAE.
cGrade 1 in severity.
dGrade 3 in severity.
eGrade 2 in severity.
TEAE treatment-emergent adverse event.
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reported a grade 1 infusion-related reaction (pruritus and
urticaria) that required temporary (48 minutes) inter-
ruption of dosing and was judged as probably related to
MEDI-546.
Viral surveillance showed a low percentage of subjects
converting from normal test results at baseline to abnor-
mal results post MEDI-546 administration: 4/31 subjects
(12.9%) for EBV and 2/24 subjects (8.3%) for HPV.
There were no abnormal CMV, HSV-1, or HSV-2 test
results throughout the study. All 7 subjects with a his-
tory of viral reactivation with HSV tested negative after
receiving MEDI-546. One subject in the 20.0 mg/kgFigure 2 Mean (±SD) serum MEDI-546 concentration. A. Single IV Adm
quantitation; SD, standard deviation. Mean data below LLOQ are not plottesingle-dose group with a history of viral reactivation de-
veloped oral herpes (grade 1) 52 days after dosing. The
infection lasted 15 days and the investigator determined
it to be unrelated to treatment.
Pharmacokinetics
After single dose administration, MEDI-546 exhibited non-
linear PK at lower dose levels (<10.0 mg/kg) (Figure 2A,
Table 3). Mean AUCinf increased more than proportionally
with MEDI-546 dose from 0.1 to 10.0 mg/kg, and pro-
portionally from 10.0 to 20.0 mg/kg. Systemic clearance
decreased from 40.8 to 4.67 mL/kg/day when the dose was
increased from 0.1 to 20.0 mg/kg. MEDI-546 terminal t1/2inistration; B. Multiple IV Administrations. LLOQ, lower limit of
d.




















1st dose 4th dose 1st dose 4th dose 1st dose 4th dose
Number of subjects 1 4 4 4 4 4 4 4 4 4 5 3
Cmax, mean (SD), μg/mL 1.97 (NA) 6.69 (1.47) 23.3 (2.22) 72.4 (13.7) 213 (44.0) 394 (83.5) 6.43 (0.470) 6.32 (1.01) 19.1 (7.80) 35.8 (15.5) 87.6 (19.3) 135 (26.5)
AUCa, mean (SD), μg · day/mL 2.45 (NA) 12.4 (4.91) 102 (14.1) 497 (105) 2610 (728) 4870 (1750) NA 10.7 (2.53) NA 159 (68.9) NA 849 (165)
CL, mean (SD), mL/kg/day 40.8 (NA) 27.4 (11.0) 9.94 (1.44) 6.26 (1.43) 4.07 (1.13) 4.67 (2.18) NA NA NA NA NA NA
t1/2, mean (SD), d 0.84 (NA) 1.24 (0.358) 2.96 (0.593) 4.07 (1.23) 7.70 (2.26) 11.8 (2.06) NA 1.06 (0.174) NA 4.94 (1.47) NA 6.28 (0.921)
aAUCinf for single-dose groups and AUC0–7 for multiple-dose groups.
AUCinf area under the serum concentration-time curve from zero to infinity; AUC0–7, AUC from day 0 to day 7 post dose administration; CL, systemic clearance; Cmax, maximum serum concentration; d, days; NA, not
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level investigated (20.0 mg/kg) the terminal t1/2 was
11.8 days.
In the multiple-dose groups, non-linear PK was also
observed at lower doses (<1.0 mg/kg/week). AUC0–7 was
more than dose proportional to MEDI-546 dose from
0.3 to 1.0 mg/kg/week, and proportional from 1.0 to
5.0 mg/kg/week (Figure 2B, Table 3). Mean t1/2 ranged
from 1.1 to 6.3 days across the multiple dose range 0.3
to 5.0 mg/kg/week. After 4 weekly doses, steady-state
was not reached, as shown by increasing trough (pre-
dose) concentrations.
Immunogenicity
Two of 21 subjects (9.5%) in the single-dose groups and 3
of 11 subjects (27.3%) in the multiple-dose groups tested
positive for ADAs following MEDI-546 administration.
Most positive titers were low (≤1:30) and transient, detect-
able only at 1 or 2 study visits. One subject in the 0.3 mg/Figure 3 Median fold change of type I IFN gene signature by visit for
in Single-Dose Groups; B. In Whole Blood in Multiple-Dose Groups; C. In Sk
IFN, interferon.kg/week multiple-dose group had persistent positive titers
of 1:240–1:960 between study days 28 and 105. Serum
MEDI-546 levels for subjects who were positive for ADA
did not appear to differ from those of subjects who were
negative for ADA, in the same dose groups.
Pharmacodynamics
At baseline, 22 and 15 subjects had positive type I IFN
gene signature score in whole blood and skin, respectively.
Subjects with elevated baseline signature in whole blood
who received MEDI-546 had suppressed gene signature;
the effect seemed to be greater when the amount of drug
was increased. All groups reached or approached gene
signature peak inhibition at day 1 post-dose (Figures 3A
and 3B).
Of the 22 subjects with a positive baseline gene signature
in whole blood, 15 were in the single-dose groups and 7 in
the multiple-dose groups. In single-dose groups ≥1.0 mg/kg,
11 subjects with positive baseline signature score in wholesubjects with positive baseline gene signature. A. In Whole Blood
in in Single-Dose Groups; D. In Skin in Multiple-Dose Groups.
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Persistent decreases until day 84 were observed in 2 of 3
subjects in the 20.0 mg/kg group (Figure 3A). In multiple-
dose groups, ≥1.0 mg/kg/week, 5 of 6 subjects had ≥70%
inhibition at day 14. The inhibition persisted until day 84
in 2 of 3 subjects in the 1.0 mg/kg/week group and both
subjects in the 5 mg/kg/week group (Figure 3B).
Of the 15 patients with a positive baseline skin signa-
ture, 11 were in the single-dose groups and 4 in the
multiple-dose groups. In single-dose groups ≥1.0 mg/kg,
MEDI-546 decreased the expression of type I IFN-indu-
cible genes in skin at day 7 (Figure 3C). In multiple-dose
groups ≥1.0 mg/kg/week, expression was decreased at day
28 (Figure 3D). Five of 11 patients in the ≥1.0 mg/kg
single-dose cohorts and all 3 patients in the 1.0 mg/kg/
week multiple-dose cohort had ≥70% inhibition.
Discussion
This is the first-time-in-human study of MEDI-546, a hu-
man monoclonal antibody targeting the IFN-mediated
pathway in SSc. MEDI-546 was administered as single
(0.1–20.0 mg/kg) and multiple (0.3–5.0 mg/kg/week) es-
calating IV doses in adult subjects with SSc, who had at
least moderate skin thickening. As MEDI-546 binds to a
novel target (IFNAR1) that plays a major role in the IFN
pathway, the starting dose of 0.1 mg/kg was recom-
mended based on a translational modeling and simulation
approach to predict the minimum anticipated biological
effect level in humans. The unoccupied IFNAR was ex-
pected to return to near baseline levels 1–2 days following
a single administration of 0.1 mg/kg MEDI-546.
In this study, MEDI-546 appeared to have an adequate
safety and tolerability profile. Most TEAEs were mild or
moderate and were reported at similar frequencies across
the dose groups. The most frequent TEAEs were upper
respiratory tract infection, headache, diarrhea, and nausea.
One infusion-related reaction (grade 1) was reported in
the 5.0 mg/kg/week multiple-dose group and resolved
after treatment with antihistamine and temporary inter-
ruption of dosing. One subject in the 1.0 mg/kg/week
multiple-dose group had a TESAE of CML, with onset
approximately 10 months after completing the study. The
event was considered possibly related to MEDI-546, with
alternate etiologies of genetic predisposition, or chemical,
drug, or radiation exposure. As this was a short-term
study, the significance of this finding is unclear and will be
monitored in further studies across SSc and other dis-
eases. Even though there is evidence suggesting that the
type I IFN pathway is involved in tumor surveillance
[28,29], to date, IFN blockade has not been associated
with CML, and there have been no reports of spontaneous
tumor formation in IFNAR-deficient mice.
The type I IFN system plays a critical role in limiting
the spread of viral infections. As such, inhibition of typeI IFN-mediated signaling may result in increased sus-
ceptibility to infections, including reactivated latent
infections. In this study, 41.2% of subjects developed
infections, most of which were grade 1 or 2 in severity,
including one grade 3 event of osteomyelitis that was
considered remotely related to MEDI-546 treatment.
The proportions of subjects who had negative viral sur-
veillance test results at baseline that changed to positive
after MEDI-546 treatment were low: 4/31 subjects for
EBV and 2/24 subjects for HPV. Positive baseline viral
test results for HSV reverted to negative for all subjects.
It is uncertain whether HPV reactivation in the 2 sub-
jects mentioned above was related to immunosuppression
from investigational product, infection during the course
of the study or as a result of a potential false positive result
arising from analytical inaccuracy of the HC2 assay. The
College of American Pathologists recently warned that
limitations of the HC2 assay can lead to 5% false-positive
results when no HPV DNA is present [30].
Positive EBV tests for the 4 subjects occurred only on
a single study day and showed no association with dose
strength or frequency. In addition, changes in these re-
sults were not associated with any trends in worsening
of clinical symptoms. Furthermore, positive baseline viral
test results for HSV reverted to negative for all subjects.
One subject with positive EBV levels at baseline that be-
came negative after initiation of MEDI-546 treatment
also showed suppression of the gene signature. Although
no increased risk of viral infections with MEDI-546 was
identified in this study, viral reactivation events are
important to monitor, and they have been defined as
adverse events of special interest that are being closely
monitored in other studies.
As with other monoclonal antibodies targeting cell-
membrane associated receptors, the PK of MEDI-546
was subject to the target-mediated clearance mechanism
(antigen sink effect) [31-34]. At lower doses (single
doses <10.0 mg/kg and multiple doses <1.0 mg/kg/week),
MEDI-546 exhibited non-linear PK. The non-linear elimi-
nation pathway presumably involves the binding of
MEDI-546 to IFNAR and the subsequent internalization
and intracellular degradation of the antibody-receptor
complex. This resulted in a more rapid systemic clea-
rance and shorter elimination half-life at lower doses. At
higher doses (single doses ≥10.0 mg/kg and multiple
doses ≥1.0 mg/kg/week), IFNAR was presumably fully
occupied and the PK of MEDI-546 became dose-propor-
tional, with a more prolonged half-life. The systemic clea-
rance of MEDI-546 decreased with dose. The presence of
ADAs was detected in 5 subjects (15.6%), but generally, posi-
tive titers were low and transient. The presence of ADAs
had no apparent impact on MEDI-546 serum PK levels.
MEDI-546 decreased type I IFN gene expression in
whole blood and skin for subjects with positive scores at
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whole blood reached or approached peak inhibition
within 1 day after dosing and persisted through day 84
in the multiple-dose groups. Although only small num-
bers of subjects received MEDI-546, there seemed to be
a dose-dependent neutralization of the type 1 IFN gene
signature in whole blood. These results support further
investigation of MEDI-546 as a key molecule that in-
hibits IFN gene expression in the treatment of SSc.
Our study had several limitations that should be taken
into account in the interpretation of these results. This
was an early phase study, with relatively low numbers of
subjects in each treatment group. Effect of MEDI-546
on measures of disease activity and patient-reported out-
comes were not determined because of the open-label,
non-placebo-controlled study design and small sample
size. The gene signature suppression should also be inter-
preted with both patient-to-patient molecular variability
and modest sample sizes (i.e. n = 1 to 4 samples maxi-
mum) in mind. In lieu of error bars, the median for each
cohort is provided (Figure 3) to illustrate the primary
trend in gene signature suppression within each cohort.
Results should also be interpreted in light of the inherent
limitations of non-randomized, open-label, uncontrolled
studies [35]. Larger, longer-term studies are needed to
establish any relationship between the inhibition of IFN-
mediated signaling and the potential occurrence of malig-
nancies. Caution is advised in extrapolating safety data
from this study to other patient populations, as SSc is
associated with a high prevalence of comorbidities [36].
Conclusions
This Phase 1 study of MEDI-546 at single (0.1–20.0 mg/kg)
and multiple (0.3–5.0 mg/kg/week, 4 doses) IV doses had
an adequate safety and tolerability profile in adults with
SSc. Administration of MEDI-546 resulted in sustained
inhibition of the type I IFN gene signature. This study
supports the continued clinical development of MEDI-546
in subjects with SSc or other IFN-related inflammatory
diseases. Further clinical studies are currently ongoing
(NCT01559090, NCT01438489).
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